Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120
Jonathan Richard, Jérémie Prévost, Catherine Bourassa, Nathalie Brassard, Marianne Boutin, Mehdi Benlarbi, Guillaume Goyette, Halima Medjahed, Gabrielle Gendron‐Lepage, Fleur Gaudette, Hung-Ching Chen, William D. Tolbert, Amos B. Smith, Marzena Pazgier, Mathieu Dubé, Andrew Clark, Walther Mothes, Daniel E. Kaufmann, Andrés Finzi
Abstract
While HIV-1-mediated CD4 downregulation protects infected cells from antibody-dependent cellular cytotoxicity (ADCC), shed gp120 binds to CD4 on uninfected bystander CD4 + T cells, sensitizing them to ADCC mediated by HIV + plasma. Soluble gp120-CD4 interaction on multiple immune cells also triggers a cytokine burst. The small molecule temsavir acts as an HIV-1 attachment inhibitor by preventing envelope glycoprotein (Env)-CD4 interaction and alters the overall antigenicity of Env by affecting its processing and glycosylation. Here we show that temsavir also blocks the immunomodulatory activities of shed gp120. Temsavir prevents shed gp120 from interacting with uninfected bystander CD4 + cells, protecting them from ADCC responses and preventing a cytokine burst. Mechanistically, this depends on temsavir's capacity to prevent soluble gp120-CD4 interaction, to reduce gp120 shedding, and to alter gp120 antigenicity. This suggests that the clinical benefits provided by temsavir could extend beyond blocking viral entry.